Omni Men's Health: a wider picture of desire
A hormone result can be fascinating. The person around it is more interesting. Kisspeptin offers an unusually good place to look at both.
Kisspeptin, testosterone and desire
Omni is a rather large word to put beside men's health. I take its ambition seriously: open the frame. A promising hormone measurement deserves company from the rest of the experiment, including whatever the participants actually felt. That wider picture is the reason for this site.
Kisspeptin gives the question some substance. In healthy men, kisspeptin-10 stimulated LH, changed its pulse frequency and raised testosterone under the studied conditions. In men with hypoactive sexual desire disorder, a separate kisspeptin-54 experiment measured brain activity, penile swelling and reported sexual desire. The measurements reach different parts of the subject. I relish the awkward fit between them.
My starting prejudice was that the hormone papers would carry the story. The desire experiments loosened that prejudice. A research programme willing to measure interest as well as endocrine activity seems to me more curious about men than an argument that ends at a blood result.
The essays
For the most immediate question, go to sexual desire. That essay stays inside a particular experiment: what was observed in men with low desire, why the physical response attracts attention, and why the combination seems to me its most absorbing feature.
The testosterone and timing page starts with a different fascination: reproductive signals arrive in pulses, and the response can change with repeated exposure. Its chart puts an early response beside a later one in the women actually studied. The difference is large enough to deserve a proper look.
For the oddest turn in the story, begin with the history of kisspeptin. The route into reproductive biology starts with cancer models. The findings beyond reproduction then move to anxiety, a measured meal and bone markers.
Safety and the longer view
A systematic review published in 2025 described kisspeptin as still awaiting regulatory approval. Its search window sets the date boundary; the review gives me no warrant for a new regulatory announcement.
The acute human findings deserve precise language. A placebo-controlled study found no significant change in anxiety, cortisol, blood pressure or heart rate during the experiment. A different study in women with hypothalamic amenorrhea documented a sharp loss of hormonal response with repeated administration. Short observations of tolerability and a changing response over time both matter to the picture.
I am optimistic about the questions kisspeptin lets people investigate. Curiosity carries me much further here than confidence about treatment. For the source records and a few suggested starting points, there is a reading list; the about page explains the limits of this editorial site.